REVISTA CHILENA DE ENFERMEDADES RESPIRATORIAS

45 / 64

249
Bibliografía
1.- Rubio D M, Schoenbaum E E, Lee L S,
Schteingart D E, Marantz P R, Anderson
K E, et al. Defining translational research: Implications
for training.
2.- International Committee of Medical
Journal Editors (ICMJE). Recommendations for
the conduct, editing and publication of scholarly work in
medical journals. Updated December 2016, disponible
en
3.- Reyes H. La relevancia del International Committee of
Medical Journal Editors (ICMJE) para las publicaciones
y la investigación médica. Rev Med Chile 2014; 142:
79-83.
4.- Clarke L A, Wraith J E, Beck M, Kolodny
E H, Pastores G M, Muenzer J, et al. A multi-
center, multinational, open-label extension study of the
safety and efficacy of Aldurazyme® (Laronidase) in
patients with mucopolysaccharidosis I. 2009;
123: 229-40. ClinicalTrials.gov
5.- Muenzer J, Wraith J E, Beck M, Giugliani
R, Harmatz P, Eng C M, et al. A phase II/III clini-
cal study of enzyme replacement therapy with idursul-
fase in mucopolysaccharidosis II (Hunter syndrome).
006; 8: 465-73.
6.- Giugliani R, Lampe C, Guffon N, Ketterid-
ge D, Leão-Teles E, et al. Natural history and gal-
sulfase treatment in mucopolysaccharidosis VI (MPS
VI, Maroteaux-Lamy syndrome)-10-year follow-up
of patients who previously participated in an MPS VI
Survey Study. 014; 164: 1953-64.
7.- Raimann E, Cornejo V, Arias C, Cabello
J F, Castro G, Fernández E, et al. Evolución
clínica de pacientes chilenos con tirosinemia tipo I
tratados con 2-(2-nitro-4-trifluorometilbenzoil)- 1,3-ci-
clohexanediona (NTBC). 2012; 140:
169-75.
8.- Masurel-Paulet A, Poggi-Bach J, Rolland
M O, Bernard O, Guffon N, Dobbelaere E,
et al. NTBC treatment in tyrosinaemia type I: long-term
outcome in French patients. 2008;
31: 81-7.
9.- Vital E M, Emery P. Abatacept in the treatment of
rheumatoid arthritis. 2006; 2:
365-75.
10.- Cohen S B, Emery P, Greenwald M W,
Dougados M, Furie R A, Genovese M C, et
al. Rituximab for rheumatoid arthritis refractory to
anti-tumor necrosis factor therapy: Results of a multi-
center, randomized, double-blind, placebo-controlled,
phase III trial evaluating primary efficacy and safety at
twenty-four weeks. 2006; 54: 2793-
806.
11.- Kappos L, Radue E-M, O’Connor P. Oral Fin-
golimod (FTY720) for relapsing multiple sclerosis.
N Engl J Med 2006;355:1124-1140. ClinicalTrials.
gov [core study] y [ex-
tension].
12.- Polman C H, O’Connor P W, Havrdova E,
Hutchinson M, Kappos L, Miller D H, et al. A
Randomized, Placebo-Controlled Trial of Natalizumab
for Relapsing Multiple Sclerosis. N Engl J Med 2006;
354: 899-910.
13.- Zimran A, Brill-Almon E, Chertkoff R,
Petakov M, Blanco-Favela F, Muñoz E T,
et al. Pivotal trial with plant cell-expressed recombinant
glucocerebrosidase, taliglucerase alfa, a novel enzyme
replacement therapy for Gaucher disease. Blood 2011;
118: 5767-73.
14.- Weinreb N J, Goldblatt J, Villalobos J,
Charrow J, Cole J A, Kerstenetzky M, et al.
Long-term clinical outcomes in type 1 Gaucher disease
following 10 years of imiglucerase treatment. J Inherit
Metab Dis 2012; 36: 543-53.
15.
et al. Agalsidase-beta therapy for advanced Fabry di-
sease: A randomized trial. Ann Intern Med 2007; 146:
77-86.
16.- Olschewski H, Simonneau G, Galiè N,
Higenbottam T, Naeije R, Rubin L J, et al.
Inhaled iloprost for severe pulmonary hypertension.
2002; 347: 322-9.
17.- Galie N, Rubin L J, Hoeper M M, Jansa P, Al-
Hiti H, Meyer G M B, et al. Long-term pulmonary
hemodynamic effects of ambrisentan in pulmonary
arterial hypertension. 008; 371: 2093-100.
ClinicalTrials.gov
18.- Klinger J R, Oudiz R J, Spence R, Despain D,
Dufton C. Treatment of patients with mildly symp-
tomatic pulmonary arterial hypertension with bosentan
(EARLY study): a double-blind, randomised controlled
trial. 2011; 108: 302-7.
19.- The IMpact-RSV Study Group. Palivizumab,
a humanized respiratory syncytial virus monoclonal
antibody, reduces hospitalization from respiratory
syncytial virus infection in high-risk infants. The
IMpact-RSV Study Group. 1998;102: 531-
7.
20.- Slamon D, Eiermann W, Robert N,
Pienkowski T, Martin M, Press M, et al. Ad-
juvant trastuzumab in HER2-positive breast cancer.
21.- Dignass A, Van Assche G, Lindsay J O, Lé-
mann M, Söderholm J, Colombel J F, et al.
The second European evidence-based consensus on the
diagnosis and management of Crohn’s disease: Current
management. Journal of Crohn’s and Colitis 2010; 4:
28-62
22.- Pickup J, Keen H. Continuous subcutaneous insulin
infusion at 25 years. Evidence base for the expanding
Declaración de laAcademia Chilena de Medicina del Instituto de Chile sobre ensayos clínicos
Rev Chil Enferm Respir 2016; 32: 244-250